ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
Acceleron Pharma Inc. (the “Company”) intends to participate in investor meetings at the 37th AnnualJ.P. MorganHealthcare Conference (the “Conference”) during the week of January7, 2019, and intends to present an overview of the Company along with its corporate priorities at the Conference on January 7, 2019.
The slide presentation to be used in investor meetingsand presented at the Conference is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The furnishing of the attached slide presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company has made and may make from time to time bypress releaseor otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate.
The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or for any other purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filing, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
ACCELERON PHARMA INC Exhibit
EX-99.1 2 xlrn20190107form8kex991.htm EXHIBIT 99.1 xlrn20190107form8kex991 Exhibit 99.1 Corporate Presentation January 7,…
To view the full exhibit click here
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
